| Prev Close | 15.25 |
| Open | 15.30 |
| Day Low/High | 14.80 / 15.30 |
| 52 Wk Low/High | 16.60 / 21.49 |
| Volume | 223.05K |
| Avg Volume | 304.80K |
| Exchange | NASDAQ |
| Shares Outstanding | 42.20M |
| Market Cap | 643.59M |
| EPS | 0.80 |
| P/E Ratio | 21.48 |
| Div & Yield | 0.50 (3.30%) |
Latest News
VIVO INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of An Investigation Concerning Possible Securities Violations By Meridian Bioscience, Inc.
The Law Offices of Vincent Wong announce the commencement of an investigation concerning whether Meridian Bioscience, Inc.
Bullish Two Hundred Day Moving Average Cross - VIVO
In trading on Monday, shares of Meridian Bioscience Inc. crossed above their 200 day moving average of $15.66, changing hands as high as $15.70 per share.
VIVO: Insiders vs. Shorts
The most recent short interest data was recently released for the 05/15/2017 settlement date, and Meridian Bioscience Inc. is one of the most shorted stocks of the Russell 3000, based on 9.88 "days to cover" versus the median component at 4.71.
VIVO SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Announces An Investigation Concerning Possible Securities Violations By Meridian Bioscience, Inc.
The Law Offices of Vincent Wong announce the commencement of an investigation concerning whether Meridian Bioscience, Inc.
Glancy Prongay & Murray LLP Commences Investigation On Behalf Of Meridian Bioscience, Inc. Investors
Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Meridian Bioscience, Inc.
INVESTOR ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Meridian Bioscience, Inc.
Levi & Korsinsky announces it has commenced an investigation of Meridian Bioscience, Inc.
Magellan Diagnostics (Meridian Bioscience, Inc., NASDAQ: VIVO) Launches National Education Initiative On Risks Of Lead Exposure For Pregnant Women
Kickoff panel highlights common risks and what obstetricians can do to help protect their patients
Meridian Bioscience Named Top Dividend Stock With Insider Buying and 3.38% Yield (VIVO)
In this series, we look through the most recent Dividend Channel ''DividendRank'' report, and then we cherry pick only those companies that have experienced insider buying within the past six months. The officers and directors of a company tend to have a unique insider's view of the business, and presumably the only reason an insider would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both.
New Testing Procedure Holds Promise As A Critical Tool In The Global Effort To Eliminate Malaria
Field laboratory-deployable molecular test up to 80,000 times more sensitive than current options
ECCMID Presentation To Demonstrate Revolutionary Breakthrough In Malaria Detection
New Testing Procedure Holds Promise As a Critical Tool in the Global Effort to Eliminate Malaria
First Week of VIVO May 19th Options Trading
Investors in Meridian Bioscience Inc. saw new options become available this week, for the May 19th expiration.
The VIVO Paradox: Analysts Bearish But Forecast 10.67% Gains
Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Meridian Bioscience Inc. .
Oversold Conditions For Meridian Bioscience (VIVO)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
